Natera, Inc. (NASDAQ:NTRA – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $256.5294.
A number of equities analysts recently issued reports on the stock. Evercore reiterated an “outperform” rating and issued a $270.00 target price on shares of Natera in a research report on Friday, May 8th. JPMorgan Chase & Co. upped their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective on the stock. Finally, Royal Bank Of Canada began coverage on Natera in a report on Thursday. They set an “outperform” rating and a $275.00 target price on the stock.
Check Out Our Latest Report on Natera
Natera Stock Performance
Insider Activity at Natera
In other news, insider Solomon Moshkevich sold 3,405 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the sale, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. The trade was a 2.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the sale, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 159,378 shares of company stock worth $34,640,860 in the last quarter. Company insiders own 5.05% of the company’s stock.
Institutional Trading of Natera
A number of hedge funds and other institutional investors have recently made changes to their positions in NTRA. NewEdge Advisors LLC boosted its holdings in Natera by 3.4% during the first quarter. NewEdge Advisors LLC now owns 5,452 shares of the medical research company’s stock worth $1,090,000 after buying an additional 179 shares in the last quarter. Groupama Asset Managment increased its holdings in shares of Natera by 3.0% in the first quarter. Groupama Asset Managment now owns 95,061 shares of the medical research company’s stock valued at $19,011,000 after buying an additional 2,805 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new stake in shares of Natera during the 1st quarter valued at $6,410,000. Bull Harbor Capital LLC acquired a new stake in shares of Natera during the 1st quarter valued at $1,543,000. Finally, Encore Global Management LP bought a new stake in shares of Natera during the 1st quarter worth $1,200,000. 99.90% of the stock is currently owned by institutional investors.
Natera Company Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Recommended Stories
- Five stocks we like better than Natera
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
